Trial Profile

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afuresertib (Primary) ; LAE 001 (Primary) ; Prednisone (Primary) ; Docetaxel
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Laekna Therapeutics

19 Aug 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, 26 patients are still in the study without radiographic tumor progression. The rPFS data is expected to be mature and will be reported at the meeting.
24 Oct 2023 Results (n=40; data cutoff date: 25 Apr 2023) from phase 1 and phase 2 portion of this trial presented at the 48th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com